Gene editing takes centre stage in FDA’s new rare disease approval pathway
The US Food and Drug Administration (FDA) has issued more information to sponsors regarding its “plausible mechanism pathway”, a new…
The US Food and Drug Administration (FDA) has issued more information to sponsors regarding its “plausible mechanism pathway”, a new…